Case number 1:23-cv-01008
Celgene Corporation et al v. Teva Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 29, 2024 | 35 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,846,628 B2; US 11,571,436 B2. (Attachments: # 1 Consent Judgment - Natco Pharma Ltd., # 2 Consent Judgment - Teva Pharmaceuticals, Inc.)(ceg) (Entered: 05/29/2024) (0) |
| May 29, 2024 | 34 | CONSENT JUDGMENT and Order of Dismissal between Plaintiffs and Defendant Natco Pharma Ltd. Signed by Judge Jennifer L. Hall on 5/29/2024. (ceg) (Entered: 05/29/2024) (4) |
| May 23, 2024 | 33 | PROPOSED Consent Judgment and Order of Dismissal of Defendant Natco Pharma Ltd., by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Michael) Modified on 5/23/2024 (ceg). (Entered: 05/23/2024) (4) |
| Apr 30, 2024 | 32 | CONSENT JUDGMENT and Order of Dismissal between Plaintiffs and Defendant Teva Pharmaceuticals, Inc. Signed by Judge Jennifer L. Hall on 4/30/2024. (ceg) (Entered: 04/30/2024) (3) |
| Apr 29, 2024 | 31 | PROPOSED Consent Judgment and Order of Dismissal (between Plaintiffs and Teva), by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Brian) Modified on 4/29/2024 (ceg). (Entered: 04/29/2024) (3) |
| Apr 8, 2024 | 30 | NOTICE OF SERVICE of Celgene Corporation, Celgene International Sarl, and Bristol-Myers Squibb Company's Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl.(Farnan, Michael) (Entered: 04/08/2024) (2) |
| Apr 8, 2024 | 29 | NOTICE of Defendant Natco Pharma, Ltd.'s Initial Disclosures Pursuant To The Delaware Default Standard Paragraph 3 by Natco Pharma Limited (Green, James) (Entered: 04/08/2024) (3) |
| Mar 26, 2024 | N/A | SO ORDERED, re 28 Stipulation and Order for Extension of Time for Plaintiffs and Natco Defendants to serve Initial Disclosures pursuant to the Delaware Default Standard for Discovery to April 8, 2024. Ordered by Judge Jennifer L. Hall on 3/26/2024. (ceg) (Entered: 03/26/2024) (0) |
| Mar 25, 2024 | 28 | STIPULATION & Proposed Order For Extension Of Time For Plaintiffs And Natco Defendants To Serve Initial Disclosures Pursuant To The Delaware Default Standard For Discovery by Natco Pharma Limited. (Green, James) (Entered: 03/25/2024) (3) |
| Mar 8, 2024 | 27 | NOTICE OF SERVICE of Plaintiffs' Identification of Accused Products and Asserted Patents filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl.(Farnan, Michael) (Entered: 03/08/2024) (2) |
| Mar 5, 2024 | 26 | PROTECTIVE ORDER. Signed by Judge Jennifer L. Hall on 3/5/2024. (ceg) (Entered: 03/05/2024) (23) |
| Mar 4, 2024 | 25 | PROPOSED Protective Order, by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Michael) Modified on 3/5/2024 (ceg). (Entered: 03/04/2024) (23) |
| Feb 28, 2024 | 24 | NOTICE OF SERVICE of Plaintiffs' Rule 26(a)(1) Initial Disclosures filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl.(Farnan, Michael) (Entered: 02/28/2024) (2) |
| Feb 28, 2024 | 23 | NOTICE OF SERVICE of Defendant Natco Pharma, Ltd's Initial Disclosures Under Fed.R.Civ.P 26(a)(1) filed by Natco Pharma Limited.(Green, James) (Entered: 02/28/2024) (3) |
| Feb 27, 2024 | 22 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Natco Pharma Limited. (Green, James) (Entered: 02/27/2024) (2) |
| Feb 23, 2024 | N/A | ***Party Natco Pharma Limited added. ***Attorney James S. Green, Jr., Andrew O. Larsen, Christopher J. Sorenson, and Jason M. Wiener for Natco Pharma Limited added. (ceg) (Entered: 02/23/2024) (0) |
| Feb 23, 2024 | 21 | SCHEDULING AND CONSOLIDATION ORDER: Celgene Corporation v. Teva Pharmaceuticals, Inc., C.A. No. 1:23-cv-01008-JLH, and Celgene Corporation v. Natco Pharma Ltd., C.A. No. 1:23-cv-01019-JLH, are consolidated for all purposes up to and including trial. Joinder of Parties due by 8/23/2024. Amended Pleadings due by 8/23/2024. Status Report due by 10/23/2024. Fact Discovery completed by 4/4/2025. Expert Discovery due by 10/13/2025. Joint Claim Construction Brief due by 10/14/2024. A Markman Hearing is set for 1/9/2025 at 10:00 AM in Courtroom 6D before Judge Jennifer L. Hall. Proposed Pretrial Order due by 2/16/2026. A Pretrial Conference is set for 2/23/2026 at 03:00 PM in Courtroom 6D before Judge Jennifer L. Hall. A 3-day Bench Trial is set for 3/2/2026 at 09:30 AM in Courtroom 6D before Judge Jennifer L. Hall. (*See Order for details). Signed by Judge Jennifer L. Hall on 2/23/2024. Associated Cases: 1:23-cv-01008-JLH, 1:23-cv-01019-JLH(ceg) (Entered: 02/23/2024) (17) |
| Feb 21, 2024 | 20 | ORAL ORDER: The Rule 16(b) Conference scheduled for February 23, 2024 is CANCELLED. Ordered by Judge Jennifer L. Hall on 2/21/2024. Associated Cases: 1:23-cv-01008-JLH, 1:23-cv-01019-JLH(ceg) (Entered: 02/21/2024) (0) |
| Feb 20, 2024 | 19 | Letter to The Honorable Judge Jennifer L. Hall from Nathan R. Hoeschen regarding Rule 16 conference set for February 23, 2024. (Hoeschen, Nathan) Modified on 2/21/2024 (ceg). (Entered: 02/20/2024) (1) |
| Feb 13, 2024 | 18 | PROPOSED Scheduling Order, by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Attachments: # 1 Letter to The Honorable Jennifer L. Hall)(Farnan, Michael) Modified on 2/13/2024 (ceg). (Entered: 02/13/2024) (0) |
| Jan 22, 2024 | N/A | ORAL ORDER: IT IS HEREBY ORDERED that the Scheduling Conference scheduled for February 5, 2024 is RESCHEDULED February 23, 2024 at 10:00 AM in Courtroom 6D before Judge Jennifer L. Hall. Ordered by Judge Jennifer L. Hall on 1/22/2024. Associated Cases: 1:23-cv-01008-JLH, 1:23-cv-01019-JLH(ceg) (Entered: 01/22/2024) (0) |
| Jan 16, 2024 | N/A | Case Reassigned to Judge Jennifer L. Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed. Associated Cases: 1:21-cv-01795-RGA, 1:23-cv-00699-RGA, 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(nms) (Entered: 01/16/2024) (0) |
| Jan 2, 2024 | 17 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 2/5/2024, at 2:00 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 1/2/2024. (nms) (Entered: 01/02/2024) (1) |
| Dec 11, 2023 | 16 | ANSWER to 15 Answer to Complaint, Counterclaim by Bristol-Myers Squibb Company, Celgene International Sarl.(Farnan, Michael) (Entered: 12/11/2023) (8) |
| Nov 20, 2023 | N/A | Pro Hac Vice Attorney Kevin J. Boyle for Teva Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) (Entered: 11/20/2023) (0) |
| Nov 20, 2023 | 15 | ANSWER to 1 Complaint and COUNTERCLAIMS against Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl, by Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) Modified on 11/20/2023 (nms). (Entered: 11/20/2023) (26) |
| Nov 17, 2023 | N/A | SO ORDERED, re 14 MOTION for Pro Hac Vice Appearance of Attorney Kevin Boyle, filed by Teva Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 11/17/2023. (nms) (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 14 | MOTION for Pro Hac Vice Appearance of Attorney Kevin Boyle - filed by Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 11/17/2023) (3) |
| Oct 26, 2023 | N/A | SO ORDERED, re 13 STIPULATION to Extend Time (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 11/20/2023). Signed by Judge Richard G. Andrews on 10/26/2023. (nms) (Entered: 10/26/2023) (0) |
| Oct 26, 2023 | 13 | STIPULATION to Extend Time - filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) Modified on 10/26/2023 (nms). (Entered: 10/26/2023) (1) |
| Oct 24, 2023 | N/A | Pro Hac Vice Attorney Ivan M. Poullaos,George C. Lombardi, and Elise M. LeCrone for Teva Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) (Entered: 10/24/2023) (0) |
| Oct 23, 2023 | N/A | SO ORDERED, re 12 MOTION for Pro Hac Vice Appearance of Attorney George Lombardi, Ivan Poullaos and Elise M. LeCrone, filed by Teva Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 10/23/2023. (nms) (Entered: 10/23/2023) (0) |
| Oct 23, 2023 | 12 | MOTION for Pro Hac Vice Appearance of Attorney George Lombardi, Ivan Poullaos and Elise M. LeCrone - filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) (Entered: 10/23/2023) (5) |
| Sep 27, 2023 | N/A | Pro Hac Vice Attorney David Mlaver for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(mpb) (Entered: 09/27/2023) (0) |
| Sep 27, 2023 | N/A | Pro Hac Vice Attorney Heather M. Petruzzi, Amy K. Wigmore, Gerard A. Salvatore, Nora Q.E. Passamaneck, Andrew J. Danford, and Li-tsung A. Chen for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(mpb) (Entered: 09/27/2023) (0) |
| Sep 26, 2023 | N/A | SO ORDERED, re 11 STIPULATION to Extend Time (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 11/6/2023). Signed by Judge Richard G. Andrews on 9/26/2023. (nms) (Entered: 09/26/2023) (0) |
| Sep 26, 2023 | 11 | STIPULATION to Extend Time - filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) Modified on 9/26/2023 (nms). (Entered: 09/26/2023) (1) |
| Sep 20, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) (Entered: 09/20/2023) (1) |
| Sep 20, 2023 | N/A | DEFICIENCY NOTICE issued by the Court to Defendant: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms) (Entered: 09/20/2023) (0) |
| Sep 20, 2023 | N/A | SO ORDERED, re 8 MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-tsung Alyssa Chen, filed by Celgene Corporation, Celgene International Sarl, Bristol-Myers Squibb Company. Signed by Judge Richard G. Andrews on 9/20/2023. (nms) (Entered: 09/20/2023) (0) |
| Sep 20, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 09/20/2023) (0) |
| Sep 19, 2023 | 9 | NOTICE of Appearance by Karen Elizabeth Keller on behalf of Teva Pharmaceuticals, Inc. (Keller, Karen) (Entered: 09/19/2023) (1) |
| Sep 18, 2023 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-tsung Alyssa Chen - filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Brian) (Entered: 09/18/2023) (9) |
| Sep 15, 2023 | 7 | SUMMONS Returned Executed by Celgene Corporation, Bristol-Myers Squibb Company, Celgene International Sarl.Teva Pharmaceuticals, Inc. served on 9/14/2023, answer due 10/5/2023. (Farnan, Michael) (Entered: 09/15/2023) (2) |
| Sep 13, 2023 | 6 | Summons Issued as to Teva Pharmaceuticals, Inc. on 9/13/2023. (mpb) (Entered: 09/13/2023) (2) |
| Sep 13, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bristol-Myers Squibb Company for Celgene Corporation; Corporate Parent Celgene Corporation for Celgene International Sarl filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (mpb) (Entered: 09/13/2023) (2) |
| Sep 13, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,846,628 B2 ;US 11,571,436 B2. (mpb) (Entered: 09/13/2023) (1) |
| Sep 13, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/11/2023. Date of Expiration of Patent: 6/3/2030 & 5/14/2029.Thirty Month Stay Deadline: 2/11/2026. (mpb) (Entered: 09/13/2023) (2) |
| Sep 13, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 09/13/2023) (3) |
| Sep 13, 2023 | 1 | Complaint* (1) |
